Kopetdaghinanes, pro-apoptotic hemiacetialic cyclomyrsinanes from Euphorbia kopetdaghi.


Journal

Fitoterapia
ISSN: 1873-6971
Titre abrégé: Fitoterapia
Pays: Netherlands
ID NLM: 16930290R

Informations de publication

Date de publication:
Oct 2020
Historique:
received: 05 03 2020
revised: 19 05 2020
accepted: 23 05 2020
pubmed: 29 5 2020
medline: 23 3 2021
entrez: 29 5 2020
Statut: ppublish

Résumé

Euphorbia kopetdaghi grows wild in the Northeast parts of Iran. Phytochemical study of its aerial parts led to the isolation of two undescribed cyclomyrsinol macrocyclic diterpenes with a new tetrahydrofuran oxidation pattern containing a hemiacetal group named: kopetdaghinane A and B. The structure of the isolated compounds was elucidated by extensive spectroscopic methods. Cytotoxic activity of kopetdaghinane A was evaluated using standard MTT assay against MCF-7 breast cancer and OVCAR-3 ovary cells. HUVEC cells were used as a normal cell line for calculation of the selectivity index. The MTT showed cyclomyrsinol diterpene has a significant cytotoxic effect with good selectivity indexes against both cell lines but with more selectivity against MCF-7 cells. Apoptosis induction by cyclomyrsinol treatment was confirmed by annexin V-FITC/PI staining, and caspase-6 activation. Western blot analysis showed that the expression of Bcl-2 was noticeably decreased in response to kopetdaghinane A treatment, while the expression of Bax protein was increased. Moreover, the apoptotic effect of cyclomyrsinol was shown to be related to ROS production, and loss of mitochondrial membrane potential (ΔΨm). Taken together, these results showed that kopetdaghinane A inhibits the growth of MCF-7 breast cancer cells through the activation of the mitochondrial apoptotic pathway and may be considered as an investigational compound in breast cancer preclinical study.

Identifiants

pubmed: 32464255
pii: S0367-326X(20)30218-5
doi: 10.1016/j.fitote.2020.104636
pii:
doi:

Substances chimiques

Antineoplastic Agents, Phytogenic 0
BAX protein, human 0
BCL2 protein, human 0
Diterpenes 0
Phytochemicals 0
Proto-Oncogene Proteins c-bcl-2 0
Reactive Oxygen Species 0
bcl-2-Associated X Protein 0
CASP6 protein, human EC 3.4.22.-
Caspase 6 EC 3.4.22.-

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

104636

Informations de copyright

Copyright © 2020 Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest I hereby also certify that I have no financial conflict connected to this article. The funding source supporting the work was acknowledged in the paper. No potential conflict of interest declared by any other authors involved in this work. Compliance with Ethics in Investigations has been applied in this work.

Auteurs

Farhad Riahi (F)

Department of Clinical Laboratory Sciences, School of Allied Medical Sciences, Tehran University of Medical Sciences, Tehran, Iran.

Nasrin Dashti (N)

Department of Clinical Laboratory Sciences, School of Allied Medical Sciences, Tehran University of Medical Sciences, Tehran, Iran.

Mustafa Ghanadian (M)

Department of Pharmacognosy, School of Pharmacy, Isfahan University of Medical Sciences, Isfahan, Iran; Phytochemistry Research Center and School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran. Electronic address: Ghannadian@gmail.com.

Mahmoud Aghaei (M)

Department of Clinical Biochemistry, School of Pharmacy & Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, Iran. Electronic address: maghaei@pharm.mui.ac.ir.

Farough Faez (F)

Department of Pharmacognosy, School of Pharmacy, Isfahan University of Medical Sciences, Isfahan, Iran.

Seyyed Mehdi Jafari (SM)

Dept. of Clinical Biochemistry, School of Medicine, Golestan University of Medical Sciences and Health Services, Golestan, Iran.

Narges Zargar (N)

Department of Clinical Biochemistry, School of Pharmacy & Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, Iran.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH